🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma

Recruitingn/aAges 18 Years - anyAllNantes University Hospital
NCT06274593 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness. To date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma. The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Men and women aged 18 and over * Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital * mean visual field deficit (MD) \>10dB Exclusion Criteria: * Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...) * PPR (retinal PanPhotocoagulation), retinal cerclage * Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa) * AMD and other macular pathologies that can lead to central visual field deficits * Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract) * Loss of fixation point preventing visual field formation Pregnant or breast-feeding women * Protected adults under guardianship or curatorship * with unreliable visual fields (false positives and false negatives \> 33%) * with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)
💊

What it tests

  • OCT
📍

Where

2 sites
CHU Nantes
Nantes, France
Jean-Baptiste Ducloyer
Nantes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy